Literature DB >> 2144203

Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.

P H Smith1, A Bono, F Calais da Silva, F Debruyne, L Denis, P Robinson, R Sylvester, T G Armitage.   

Abstract

This article reviews the serial bone scans of 149 of 327 patients entered into a randomized prospective trial comparing orchidectomy versus zoladex and flutamide in patients with metastatic prostatic cancer. Attention is drawn to the difficulty of evaluating the response rate and of the importance of tumor load in determining survival. The use of sequential bone scans once the diagnosis of metastatic disease has been confirmed is of questionable value as the scans are expensive and contribute little to the further management of the patient in the absence of symptoms requiring relief.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144203     DOI: 10.1002/cncr.1990.66.s5.1009

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

Authors:  Howard I Scher; Michael J Morris; William K Kelly; Lawrence H Schwartz; Glenn Heller
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

Review 2.  Novel tracers and their development for the imaging of metastatic prostate cancer.

Authors:  Andrea B Apolo; Neeta Pandit-Taskar; Michael J Morris
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

Review 3.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

4.  How significant are serial bone scans in monitoring advanced prostatic cancer?

Authors:  S Tekgül; H Ozen; R Ozyavuz; M Bakkaloğlu; D Remzi
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

5.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

6.  Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.

Authors:  Eija Sutinen; Martti Nurmi; Anne Roivainen; Matti Varpula; Tuula Tolvanen; Pertti Lehikoinen; Heikki Minn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-11-20       Impact factor: 9.236

7.  Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy.

Authors:  Satyajit Kosuri; Naveed H Akhtar; Michael Smith; Joseph R Osborne; Scott T Tagawa
Journal:  Adv Urol       Date:  2012-05-28

8.  [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

Authors:  Marino Cimitan; Roberto Bortolus; Sandro Morassut; Vincenzo Canzonieri; Antonio Garbeglio; Tanja Baresic; Eugenio Borsatti; Annalisa Drigo; Mauro G Trovò
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-25       Impact factor: 10.057

9.  Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.

Authors:  E H Hernes; S D Fosså; S Vaage; P Ogreid; A Heilo; E Paus
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study.

Authors:  Anna K Campos; Hilde D Hoving; Stefano Rosati; Geert J L H van Leenders; Igle J de Jong
Journal:  Int J Mol Sci       Date:  2016-09-29       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.